- Home
- KROS vs ANAB Comparison
KROS vs ANAB Comparison
Compare KROS & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KROS
- ANAB
- Stock Information
- Founded
- KROS 2015
- ANAB 2005
- Country
- KROS United States
- ANAB United States
- Employees
- KROS N/A
- ANAB N/A
- Industry
- KROS Biotechnology: Pharmaceutical Preparations
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- KROS Health Care
- ANAB Health Care
- Exchange
- KROS Nasdaq
- ANAB Nasdaq
- Market Cap
- KROS 565.0M
- ANAB 621.1M
- IPO Year
- KROS 2020
- ANAB 2017
- Fundamental
- Price
- KROS $14.51
- ANAB $26.59
- Analyst Decision
- KROS Buy
- ANAB Buy
- Analyst Count
- KROS 13
- ANAB 10
- Target Price
- KROS $20.63
- ANAB $49.00
- AVG Volume (30 Days)
- KROS 450.7K
- ANAB 526.3K
- Earning Date
- KROS 08-06-2025
- ANAB 08-08-2025
- Dividend Yield
- KROS N/A
- ANAB N/A
- EPS Growth
- KROS N/A
- ANAB N/A
- EPS
- KROS 0.11
- ANAB N/A
- Revenue
- KROS $214,713,000.00
- ANAB $111,872,000.00
- Revenue This Year
- KROS $5,390.70
- ANAB N/A
- Revenue Next Year
- KROS N/A
- ANAB $24.39
- P/E Ratio
- KROS $133.17
- ANAB N/A
- Revenue Growth
- KROS 91657.70
- ANAB 387.20
- 52 Week Low
- KROS $9.12
- ANAB $12.21
- 52 Week High
- KROS $72.37
- ANAB $41.31
- Technical
- Relative Strength Index (RSI)
- KROS 58.66
- ANAB 62.36
- Support Level
- KROS $14.18
- ANAB $25.48
- Resistance Level
- KROS $14.85
- ANAB $28.50
- Average True Range (ATR)
- KROS 0.55
- ANAB 1.22
- MACD
- KROS 0.04
- ANAB -0.02
- Stochastic Oscillator
- KROS 71.78
- ANAB 57.65
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).